Cell therapy (CAR-T) · Kills target cells, directed at Claudin 18.2 (CLDN18) · developed by Legend Biotech USA
LB1908 is an autologous T-cell therapy engineered to express a chimeric antigen receptor specific for Claudin 18.2, a tight junction protein expressed on a variety of tumor cells. The engineered cells recognize and selectively kill Claudin 18.2-expressing tumor cells and are being studied in gastric, gastroesophageal-junction, esophageal and pancreatic cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05539430 | Phase 1 | Gastric Cancer | Active not recruiting | LEGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Esophageal CancerGastric CancerGastroesophageal-junction CancerPancreatic Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the LEGN page.
See LEGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LEGN catalysts and pipeline →